Clinical Trial Update: ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions [Phase 3]

View source ↗

Summary

Phase 3 study ELEMENT-MDS evaluating the efficacy and safety of Luspatercept in participants with Myelodysplastic Syndromes and anemia not receiving blood trans…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: RECRUITING